T1	Condition 0 8	Pregnant
T2	Post-eligibility 11 127	Not have informed consent for the present clinical trial, or do not fully understand the meaning of informed consent
T3	Condition 135 162	acute myocardial infarction
T4	Condition 168 188	ST segment elevation
T5	Temporal 189 237	in the first 12 hours from the onset of symptoms
T6	Reference_point 216 237	the onset of symptoms
R1	Has_index Arg1:T5 Arg2:T6	
R2	AND Arg1:T3 Arg2:T4	
R3	Has_temporal Arg1:T3 Arg2:T5	
T7	Condition 249 272	acute coronary syndrome
T8	Condition 290 311	acute pulmonary edema
T9	Condition 313 330	cardiogenic shock
T10	Condition 350 373	ventricular arrhythmias
T11	Qualifier 340 349	malignant
R4	Has_qualifier Arg1:T10 Arg2:T11	
*	OR T8 T9 T10
T12	Scope 290 374	acute pulmonary edema, cardiogenic shock and / or malignant ventricular arrhythmias.
R5	Has_scope Arg1:T7 Arg2:T12	
T13	Procedure 387 410	cardiac catheterization
T14	Qualifier 451 458	femoral
T15	Qualifier 460 468	brachial
T16	Qualifier 472 477	ulnar
*	OR T14 T15 T16
T17	Scope 451 477	femoral, brachial or ulnar
R6	Has_scope Arg1:T13 Arg2:T17	
T18	Non-query-able 480 615	Patients in whom first attempt of arterial puncture is performed by 2nd year interventional cardiology fellow or by physician in charge
T19	Non-query-able 618 657	Participating in another clinical trial
T20	Condition 663 671	allergic
T21	Drug 701 714	nitroglycerin
T22	Drug 724 732	nitrates
*	OR T21 T22
T23	Scope 701 732	nitroglycerin or other nitrates
T24	Condition 680 697	contraindications
*	OR T20 T24
T25	Scope 663 697	allergic or have contraindications
R7	Has_scope Arg1:T25 Arg2:T23	
T26	Drug 739 768	phosphodiesterase 5 inhibitor
T27	Drug 770 780	sildenafil
T28	Drug 782 791	tadalafil
T29	Drug 793 801	avanafil
T30	Drug 803 813	vardenafil
*	OR T27 T28 T29 T30
T31	Scope 770 814	sildenafil, tadalafil, avanafil, vardenafil)
R8	Subsumes Arg1:T26 Arg2:T31	
T32	Temporal 830 864	within 72 hours prior to the study
T33	Reference_point 859 864	study
R9	Has_index Arg1:T32 Arg2:T33	
R10	Has_temporal Arg1:T26 Arg2:T32	
